Articles published by Abdera Therapeutics Inc.

Abdera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13

December 18, 2025

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer

September 09, 2025

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

July 08, 2025

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting

April 23, 2025

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 09, 2025

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

June 27, 2024

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

May 23, 2024

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics Expands Management Team and Board of Directors

January 30, 2024

From Abdera Therapeutics Inc.

Via Business Wire

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

April 20, 2023

From Abdera Therapeutics Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Abdera Therapeutics Inc.

Starting at $3.75/week.

Subscribe Today